L
Larimar Therapeutics D
D
LRMR
1.96500
USD
0.10
(5.08%)
مغلق
حجم التداول
32,229
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
125,814,808
العنوان: Larimar Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.